EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ligand‐Based CAR ‐T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies

Manaka Shinagawa, Koichi Hirabayashi iD, Marina Fujioka, Kyosuke Kamijo, Natsuki Uchiyama, Yusuke Yokokawa, Yasuhiro Tanaka, Motoki Ono, Thanyavi Chinsuwan iD, Ryoichi Asaka, Aiko Hasegawa, Miyuki Tanaka und 5 weitere

Cancer Science · 2025-08 · 116 (8) · 2243-2255

DOI: 10.1111/cas.70106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 19.05.2025. Verfasst von Manaka Shinagawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan. Hauptthemen laut MEDLINE: ErbB Receptors, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Genital Neoplasms, Female. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) has been reported to be overexpressed in gynecologic malignancies. However, the clinical efficacy of existing molecular EGFR‐targeted therapies against gynecologic malignancies has not been demonstrated. In this study, we investigated the antitumor effects of ligand‐based EGFR chimeric antigen receptor (CAR)‐T cells on gynecologic malignancies. First, we evaluated EGFR expression in patient samples using immunohistochemistry. EGFR positivity was observed in 41%, 82%, and 79% of ovarian, endometrial, and cervical cancer in patient samples, respectively. Second, we generated ligand‐based EGFR CAR‐T cells via piggyBac ‐mediated gene transfer. EGFR CAR‐T cells were successfully generated with high CAR positivity and a high proportion of naïve/stem cell memory‐like T cells. Finally, we investigated the antitumor effects of EGFR CAR‐T cells on gynecologic malignancies. EGFR CAR‐T cells were co‐cultured with six EGFR‐positive gynecologic cancer cell lines. The growth of all six gynecologic cancer cell lines was significantly suppressed by EGFR CAR‐T cells compared to mock T cells. In in vivo studies, tumor‐bearing mice implanted with gynecologic cancer cell lines in their intraperitoneal cavity were administered EGFR CAR‐T cells, CD19 CAR‐T cells, or PBS intraperitoneally. Mice treated with EGFR CAR‐T cells displayed a significantly decreased tumor burden compared to those treated with either CD19 CAR‐T cells or PBS. Additionally, mice treated with EGFR CAR‐T cells had a significantly longer survival than the other groups. In summary, ligand‐based EGFR CAR‐T cells may be a promising therapy for various gynecologic malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsReceptors, Chimeric AntigenImmunotherapy, AdoptiveGenital Neoplasms, FemaleT-LymphocytesFemaleAnimalsHumansMiceCell Line, TumorXenograft Model Antitumor AssaysLigands

Stichwörter der Autor:innen

piggyBacCAR‐T cellsEGFRgynecologic malignancyligand‐based

Substanzen

ErbB ReceptorsReceptors, Chimeric AntigenEGFR protein, humanLigands

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Center for Advanced Research of Gene and Cell Therapy in Shinshu University (CARS), Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Microbiology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
  • Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Matsumoto, Japan.

ORCID-Profile: Koichi Hirabayashi, Thanyavi Chinsuwan, Tsutomu Miyamoto

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Shinagawa, M., Hirabayashi, K., Fujioka, M., Kamijo, K., Uchiyama, N., Yokokawa, Y., Tanaka, Y., Ono, M., Chinsuwan, T., Asaka, R., Hasegawa, A., Tanaka, M., Murakami, T., Yagyu, S., Miyamoto, T., Shiozawa, T., & Nakazawa, Y. (2025). Ligand‐Based CAR ‐T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies. Cancer Science, 116(8), 2243-2255. https://doi.org/10.1111/cas.70106

Vancouver

Shinagawa M, Hirabayashi K, Fujioka M, Kamijo K, Uchiyama N, Yokokawa Y, et al. Ligand‐Based CAR ‐T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies. Cancer Science. 2025;116(8):2243-2255. doi:10.1111/cas.70106

BibTeX
@article{Shinagawa2025,
  author = {Shinagawa, Manaka and Hirabayashi, Koichi and Fujioka, Marina and Kamijo, Kyosuke and Uchiyama, Natsuki and Yokokawa, Yusuke and Tanaka, Yasuhiro and Ono, Motoki and Chinsuwan, Thanyavi and Asaka, Ryoichi and Hasegawa, Aiko and Tanaka, Miyuki and Murakami, Takashi and Yagyu, Shigeki and Miyamoto, Tsutomu and Shiozawa, Tanri and Nakazawa, Yozo},
  title = {Ligand‐Based CAR ‐T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies},
  journal = {Cancer Science},
  year = {2025},
  volume = {116},
  number = {8},
  pages = {2243--2255},
  doi = {10.1111/cas.70106}
}
Kostenlos starten →